Gilead Sciences, Inc. (GILD) Stake Lowered by Notis McConarty Edward

Notis McConarty Edward cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,197 shares of the biopharmaceutical company’s stock after selling 1,485 shares during the quarter. Notis McConarty Edward’s holdings in Gilead Sciences were worth $1,232,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Penserra Capital Management LLC increased its stake in Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Gilead Sciences during the 2nd quarter worth approximately $147,000. Hanson & Doremus Investment Management increased its stake in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in Gilead Sciences by 29.3% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares in the last quarter. Finally, Rowland & Co. Investment Counsel ADV bought a new stake in Gilead Sciences during the 2nd quarter worth approximately $153,000. 75.94% of the stock is owned by institutional investors.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.56, for a total transaction of $6,054,372.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. In the last three months, insiders sold 494,999 shares of company stock valued at $37,404,139. 1.30% of the stock is currently owned by insiders.

A number of analysts recently issued reports on GILD shares. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. Royal Bank of Canada initiated coverage on Gilead Sciences in a research report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target for the company. JPMorgan Chase & Co. set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Wells Fargo & Co reaffirmed a “market perform” rating and set a $81.00 price target (up previously from $73.00) on shares of Gilead Sciences in a research report on Thursday, August 31st. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $85.03.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.71 on Tuesday. The company has a market capitalization of $94,978.82, a P/E ratio of 8.28, a PEG ratio of -1.22 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.75 EPS. analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.86%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is presently 23.69%.

ILLEGAL ACTIVITY NOTICE: “Gilead Sciences, Inc. (GILD) Stake Lowered by Notis McConarty Edward” was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/12/26/gilead-sciences-inc-gild-stake-lowered-by-notis-mcconarty-edward.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit